Sam Cytryn, MD, of Memorial Sloan Kettering Cancer Center, discusses the impact of the October 2024 FDA approval of zolbetuximab for first-line treatment of advanced gastric and gastroesophageal junction adenocarcinomas, emphasizing its role in a personalized approach to care.
GI Oncology Now
The leading medical news resource for practicing oncologists and health care providers treating gastrointestinal malignancies
Advertisement
Latest News
A recent study utilized patient data from 13 medical centers in a biomarker analysis of 1L ICIs with & without ...
A recent observational study determined if there is a correlation between the improvement of ADR and lower rates of CRC.
The designation is based on positive results from an ongoing collaborative trial between GSK and MSK Cancer Center.
Dr. Joseph Cullen discusses the combination of vitamin C with gemcitabine and nab-paclitaxel for pancreatic cancer.
Rising HCC mortality rates in the US highlight stark disparities across age, sex, race, and liver disease etiologies.
Both of the double-blind, multicenter trials evaluated the major efficacy outcomes of PFS and OS.
The GAP system was found to predict actionable genetic alterations including FGFR2 and IDH.
Campylobacter bacteria have been found to be enriched in primary CRC lesions of patients with metastasis.
The phase 3 KEYNOTE-177 study compared the efficacy of pembrolizumab with chemotherapy for the treatment of MSI-H/dMMR mCRC.
The survival rate benefit increased over time for patients treated with TTFields, with a 13% improvement in OS at 12 months.
Advertisement
Roundtable Discussions
Oncology Brothers Event Coverage
GI Oncology Now has exclusive coverage of Advancement in Oncology: Today’s Data for Tomorrow’s Practice, the first event co-hosted by The Oncology Brothers and Mashup Media. Review the breakthrough data on gastrointestinal cancers presented at the event and insights from esteemed experts that bridge the gap between research and practice for community oncologists.
Conference Coverage
The latest news and research updates in GI cancer treatment from the ESMO Congress 2024
The latest news and research updates in GI cancer treatment from the ASCO 2024 Annual Meeting
GI Oncology Now reviews education from ASCO GI 2024, featuring the latest advances in the field of GI cancer research.
GI Oncology Now reviews education from ISGIO 2023, featuring the latest advances in the field of GI cancer research.
Expert Interviews
Advertisement
Advertisement
Editorial Advisory Board
Christopher Lieu, MDEditor | Co-Director of Gastrointestinal Medical Oncology at University of Colorado Medicine
Benjamin Weinberg, MD, FACPEditor | Associate Professor of Medicine at Lombardi Comprehensive Cancer Center
Zev Wainberg, MD, MScEditor | Co-Director of Gastrointestinal Oncology at the University of California, Los Angeles
© 2024 Mashup Media, LLC, a Formedics Property. All Rights Reserved.